Eli Lilly (LLY) Shares Fall Over 15% in May
FXOpen
The share price of Eli Lilly and Company (LLY), the world’s largest pharmaceutical company, has seen a sharp shift in market sentiment:
→ From its April low to high, LLY shares rose by over 30%;
→ However, since the start of May, the LLY stock price has dropped more than 15% — the closing price on the last trading day of April was around $895, while today the share is trading near $775.
Why Are Eli Lilly (LLY) Shares Falling?
The decline can be attributed to three key factors:
1→ Q1 Earnings Report: Although the company reported earnings per share above expectations ($3.34 vs $3.25), investors may have been concerned by significantly higher spending on research and development.
2→ Competitor Partnership: CVS Health’s announcement that it will offer Novo Nordisk’s Wegovy instead of Lilly’s Zepbound added further pressure to LLY shares.
3→ Sector Sentiment: Broader biotech sentiment turned negative following reports that the Trump administration is considering a pricing model that would cap drug prices based on lower rates in other countries.
The media is also discussing upcoming decisions from Vinay Prasad, the new head of the FDA division overseeing vaccines and gene therapy.
Technical Analysis: Eli Lilly (LLY) Share Chart
Key price movements (marked on the chart) justify the formation of a downward channel.
On the one hand, bearish sentiment may intensify in light of recent developments. The median line of the channel could act as resistance to any upward movement.
On the other hand, bulls may find support around the $765 level — a former resistance point and the boundary between two price gaps.
Buy and sell stocks of the world's biggest publicly-listed companies with CFDs on FXOpen’s trading platform. Open your FXOpen account now or learn more about trading share CFDs with FXOpen.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Stay ahead of the market!
Subscribe now to our mailing list and receive the latest market news and insights delivered directly to your inbox.
Latest articles
September's Central Bank Divide: Where Could FX Divergence Emerge?
In this video, Gary Thomson explores the key September central bank meetings and whether policy divergence could impact major FX pairs.
👉 Key topics covered:
✔️ ECB Decision — 10 September — Markets are pricing a high probability of a 25-basis-point hike. Will the
Microsoft: AI Payoff or AI Overspend — The Chart Weighs In
Microsoft's stock has lived two very different lives in the space of a month. On July 30, shares surged 15.5% in a single session, their biggest one-day jump since 2020, wiping out nearly all of 2026's earlier losses, after
XAG/USD Analysis: Triangle Breakout Attempt Amid US Treasury Buybacks
On 19 August, the US Treasury announced that it would double the volume of long-term government bond buybacks. The measure led to a noticeable decline in yields at the longer end of the curve and forms part of the Treasury’